VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Tozuleristide
Phase 2
Peptide
B
Blaze Bioscience Inc.
1
Indications
4
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Central Nervous System Tumor
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Central Nervous System Tumor
Phase 2
Completed
Clinical
Trials by Indication
[1]
ESS
1 trial
Expanded Access for BLZ-100 (Tozuleristide)
No longer available
·
B
Blaze Bioscience Inc.
·
·
NCT04343274
CNS Tumors
1 trial
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Completed
·
B
Blaze Bioscience Inc.
·
Phase 2/3
·
NCT03579602
·
118 enrolled
Squamous Cell Cancer
1 trial
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
Terminated
·
U
University of Washington
·
Phase 1/2
·
NCT05316688
·
8 enrolled
Central Nervous System Tumor
1 trial
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Completed
·
J
John Yu
·
Phase 2
·
NCT04743310
·
50 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
4 trial records for Tozuleristide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Tozuleristide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Tozuleristide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Blaze Bioscience Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Peptide
[2]
Highest Phase
Phase 2
[1]
Company
B
Blaze Bioscience Inc.
Related News